In terms of treatment, diabetic NAFLD patients are treated with PPARγ-agonists thiazolidinedione, which acts as an insulin sensitizer that reduces lipid release and increases lipid uptake, storage and reduces hepatic gluconeogenesis (Vanni et al., 2010). The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.